文献速递儿童感染儿童呼吸

住院流感患儿早期使用奥司他韦与结局改善的关联

Association of Early Oseltamivir With Improved Outcomes in Hospitalized Children With Influenza, 2007-2020.
PubMed 文献 · JAMA Pediatr · 2022-11-07

经倾向评分逆概率加权后,早期奥司他韦与更短住院时间、更低7日再入院、晚期ICU转入及死亡或ECMO复合结局风险相关。

要点

  • 早期奥司他韦组住院中位3天,未早期组4天,IPTW模型比值为0.52(95%CI 0.52-0.53)。
  • 早期奥司他韦与7日再入院(3.5% vs 4.8%;aOR 0.72)、晚期ICU转入(2.4% vs 5.5%;aOR 0.41)、死亡或ECMO(0.9% vs 1.4%;aOR 0.63)风险更低相关。
  • 结果支持当前对流感住院儿童使用奥司他韦的推荐。

核心结论

  • 住院流感患儿早期使用奥司他韦与更短住院时间及更低7日再入院、晚期ICU转入、ECMO使用和死亡风险相关。

研究设计与样本

  • 早期奥司他韦定义为住院第0或1天使用奥司他韦。
  • 采用基于倾向评分的逆概率治疗加权(IPTW)处理适应证混杂,并用混合效应模型比较结局。

主要发现

  • 早期奥司他韦组住院中位3天 vs 4天,IPTW模型比值0.52(95%CI 0.52-0.53)。
  • 7日全因再入院3.5% vs 4.8%,aOR 0.72(95%CI 0.66-0.77)。
  • 晚期(住院第2天或以后)ICU转入2.4% vs 5.5%,aOR 0.41(95%CI 0.37-0.46)。
  • 死亡或ECMO复合结局0.9% vs 1.4%,aOR 0.63(95%CI 0.54-0.73)。

关键数值与推荐

  • 主要结局为住院时间(日历天)。
  • 次要结局包括7日再入院、晚期ICU转入及院内死亡或ECMO使用的复合结局。
  • 按年龄、复杂慢性病、早期危重病情及哮喘史进行高风险亚组比较。

临床怎么用

  • 对流感住院儿童可考虑在住院第0或1天尽早使用奥司他韦,以缩短住院时间并降低再入院、ICU转入及死亡或ECMO风险。

局限性

  • 为回顾性研究,即使采用倾向评分加权仍可能存在残余混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Oseltamivir is recommended for all children hospitalized with influenza, despite limited evidence supporting its use in the inpatient setting. OBJECTIVE: To determine whether early oseltamivir use is associated with improved outcomes in children hospitalized with influenza. DESIGN, SETTING, AND PARTICIPANTS: This multicenter retrospective study included 55 799 children younger than 18 years who were hospitalized with influenza from October 1, 2007, to March 31, 2020, in 36 tertiary care pediatric hospitals who participate in the Pediatric Health Information System database. Data were analyzed from January 2021 to March 2022. EXPOSURES: Early oseltamivir treatment, defined as use of oseltamivir on hospital day 0 or 1. MAIN OUTCOMES AND MEASURES: The primary outcome was hospital length of stay (LOS) in calendar days. Secondary outcomes included 7-day hospital readmission, late (hospital day 2 or later) intensive care unit (ICU) transfer, and a composite outcome of in-hospital death or use of extracorporeal membrane oxygenation (ECMO). Inverse probability treatment weighting (IPTW) based on propensity scoring was used to address confounding by indication. Mixed-effects models were used to compare outcomes between children who did and did not receive early oseltamivir treatment. Outcomes were also compared within high-risk subgroups based on age, presence of a complex chronic condition, early critical illness, and history of asthma. RESULTS: The analysis included 55 799 encounters from 36 hospitals. The median (IQR) age of the cohort was 3.61 years (1.03-8.27); 56% were male, and 44% were female. A total of 33 207 patients (59.5%) received early oseltamivir. In propensity score-weighted models, we found that children treated with early oseltamivir had shorter LOS (median 3 vs 4 days; IPTW model ratio, 0.52; 95% CI, 0.52-0.53) and lower odds of all-cause 7-day hospital readmission (3.5% vs 4.8%; adjusted odds ratio [aOR], 0.72; 95% CI, 0.66-0.77), late ICU transfer (2.4% vs 5.5%; aOR, 0.41; 95% CI, 0.37-0.46), and the composite outcome of death or ECMO use (0.9% vs 1.4%; aOR, 0.63; 95% CI, 0.54-0.73). CONCLUSIONS AND RELEVANCE: Early use of oseltamivir in hospitalized children was associated with shorter hospital stay and lower odds of 7-day readmission, ICU transfer, ECMO use, and death. These findings support the current recommendations for oseltamivir use in children hospitalized with influenza.

来源:JAMA Pediatr,查看原文。版权归原作者所有。

引用

  1. Walsh PS, Schnadower D, Zhang Y, et al. Association of Early Oseltamivir With Improved Outcomes in Hospitalized Children With Influenza, 2007-2020. JAMA Pediatr. 2022. PMID: 36121673. doi:10.1001/jamapediatrics.2022.3261

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。